The treatment of kidney cancer |
|
|
IPC classes for russian patent The treatment of kidney cancer (RU 2188026):
A method of treating breast cancer / 2188025
The invention relates to medicine, namely to Oncology, and can be used in the treatment of breast cancer
The method of treatment of testicular cancer / 2188002
The invention relates to medicine, namely to oncourology, and can be used to treat patients with cancer at different stages of the neoplastic process
 Drug-based tamoxifen / 2188000
The invention relates to medicine, in particular to methods for the preparation on the basis of tamoxifen, which is one of the main contemporary antiestrogens, used mainly in the treatment of cancer
 Stable crystalline salts of tetrahydrofolate acid (options), the method of production thereof and pharmaceutical composition / 2187508
The invention relates to new stable crystalline calcium or magnesium salts of (6R,S),(6S) - or (6R)-tetrahydrofolate acid, method for their production and pharmaceutical compositions based on them
 Cytotoxic agents / 2187499
The method of photodynamic therapy and applicator for its implementation / 2187347
The invention relates to medicine, and more specifically to photodynamic therapy, and can be used in Oncology and dermatology
 The way to obtain the drug on the basis of strontium-89 / 2187336
The invention relates to the technology of pharmaceutical preparations containing radioactive substances, and can be used for therapy of oncological diseases, as well as to obtain
 sources used in engineering and biological research
 Inhibitors prenyltransferase / 2186776
The invention relates to compounds of formula (I) and (II) the value of the radicals R1-R18presented in the description, with the ability to inhibit prenyltransferase
A method of treating prostate cancer / 2185831
The invention relates to medicine, namely to Oncology, and can be used to treat prostate cancer
 The agent with antitumor activity / 2185819
The invention relates to medicine, namely to drugs with antitumor activity
A method of treating breast cancer / 2188025
The invention relates to medicine, namely to Oncology, and can be used in the treatment of breast cancer
The method of treatment of testicular cancer / 2188002
The invention relates to medicine, namely to oncourology, and can be used to treat patients with cancer at different stages of the neoplastic process
The way efferent-quantum therapy / 2187340
The invention relates to medicine, transfusion medicine and can be used as cryoprecipitates
A method of treating prostate cancer / 2185831
The invention relates to medicine, namely to Oncology, and can be used to treat prostate cancer
The method of treatment of lung cancer / 2184555
The invention relates to medicine, namely to Oncology, and can be used in the treatment of locally advanced lung cancer
 The method of complex treatment of acute pyelonephritis puerperas / 2183464
The invention relates to medicine, namely to obstetrics and urology
A method of treatment of soft tissue sarcomas / 2183461
The invention relates to medicine, namely to Oncology, and can be used in the treatment of malignant soft tissue tumors with an unfavorable course of the disease
 The way to prevent septic complications in cardiac surgery patients / 2181606
The invention relates to medicine and can be used for the prevention and treatment of postoperative septic complications in cardiac surgery patients
 Method for the treatment of toxic hepatitis in patients with chronic addiction / 2180598
The invention relates to medicine, Hepatology, to methods of treatment of toxic hepatitis in patients with chronic addiction
Composition for in vitro processing of biological fluids and method for producing the magnetic sorbent for its implementation (options) / 2178313
The invention relates to medicine and can be applied for purification of biological fluids
A method of treating breast cancer / 2188025
The invention relates to medicine, namely to Oncology, and can be used in the treatment of breast cancer
|
(57) Abstract: The invention relates to medicine, namely to oncourology, and can be used to treat patients with renal cell carcinoma at different stages of the neoplastic process. Proposed in the preoperative period to polychemotherapy according to the scheme: vincristine 1.4 mg/m2/inkjet - day 1; 150 ml of autologous blood type 70 mg/m2of adriamycin, incubated the mixture for 30 min, is re-infused in/drip - 2nd day; 500 mg depo-provera is injected into/m - 4 days; 7-10 days to produce radical nephrectomy, and 7-10 days after the operation, repeat the above polychemotherapy, autohemotherapy and the introduction of depo-provera. The method allows to increase the effectiveness of treatment, to reduce the toxic manifestations, complications of hormonal nature, to increase relapse-free period, to reduce the possibility of metastasis. The invention relates to medicine, in particular to oncourology, and can be used to treat patients with renal cell carcinoma at different stages of the neoplastic process by surgery and cytotoxic agents. Known "Method of treatment of kidney cancer generalized phase opuholevidnoe systemic polychemotherapy according to the following scheme: adriamycin - 75 mg/m2in/in - in day 1, vincristine 1.4 mg/m2in/in the 1st, 8th and 15th days; depo-provera - 50 mg/m in the 1st, 8th and 15th days, followed by repetition of the course in 4 weeks. The disadvantages of this method are the following: this method currently used for the treatment of inoperable patients with renal cell cancer; the duration of treatment associated with the need for 4-5 courses of polychemotherapy (PCT), sometimes the inability to complete a course of treatment due to the serious condition of the patients; the need for additional courses of chemotherapy; low clinical effect, high incidence of complications and toxic effects - nausea, vomiting, leukopenia, high cardiotoxicity; short relapse-free period, metastasis and progression of the process. Known "Method of treatment of kidney cancer (see kN. Garin A. M., Chlenov A. C., Gabari D. H. "Handbook of anticancer drug therapy", 1993, page 49), we have chosen as a prototype, which consists in the use of hormone replacement drug depo-provera - 500 mg/m 1 time per week for several months. This method of treatment of patients with renal cell carcinoma limited to the use only of this drug on different the clinical effect, complications of hormonal nature, associated with drug relapse and metastases in the early stages after treatment. All these disadvantages of the known methods of treatment of renal cell cancer in different stages of tumor require further improvement of treatment methods. The aim of the invention is to increase the effectiveness of treatment, which consists in reducing the toxic manifestations of disturbance of the hormonal and immune status, to increase the survival period, reducing metastasis. This objective is achieved in that in the preoperative period spend polychemotherapy (PCT) according to the scheme: vincristine 1.4 mg/m2/inkjet - day 1; 150 ml of autologous blood patient add 70 mg/m2of adriamycin, incubated the mixture for 30 min, is re-infused in/drip - 2nd day; 500 mg depo-provera is injected into/m - 4 days; 7-10 days to produce radical nephrectomy, and 7-10 days after the operation, repeat the above autohemotherapy and the introduction of depo-provera. The invention of "a Method for the treatment of kidney cancer" is new, because it is unknown the level of medicine in the field of chemotherapy and x is operationem period spend polychemotherapy according to the scheme: vincristine 1.4 mg/m2/inkjet - day 1; 150 ml of autologous blood type 70 mg/m2of adriamycin, incubated the mixture for 30 min, is re-infused in/drip - 2nd day; 500 mg depo-provera/m - 4 days; 7-10 days to produce radical nephrectomy, and 7-10 days after the operation, repeat the above polychemotherapy, autohemotherapy and the introduction of depo-provera. Thus, the novelty of the invention in the application of autohemotherapy in combination with hormonal drug depo-provera in the preoperative and postoperative periods. The invention involves an inventive step, as for a specialist urologist-oncologist is not obvious from the level of development of medicine, in particular in oncourology, in the treatment of renal cell cancer in the preoperative and postoperative periods of chemotherapy and hormonal means in combination with autohemotherapy. Reducing the toxic effects of chemotherapy, hormonal and immune disorders, lengthening relapse-free and resetstatistics period, the authors associated with the two procedures autohemotherapy. The invention is not obvious, not the next level of modern medicine, it is not known neither in the world nor in SN is iminimum and can be used in health care in cancer research institutes, the breast care clinics and other medical institutions for the treatment of renal cell carcinoma. "A method for the treatment of kidney cancer" as follows: patients with kidney cancer in the preoperative period spend polychemotherapy according to the scheme: vincristine 1.4 mg/m2/inkjet - 1st day, 2nd day, make the blood of the patient in a special bottle with logician in the amount of 150 ml in a bottle with blood and logician add adriamycin at the rate of 70 mg/m2produce the incubation mixture in thermostat at t=36,5-37oC for 30 min, followed by reinfusing intravenous drip; on the 4th day administered depo-provera - 500 mg intramuscularly. 7-10 days after administration perform surgery radical nephrectomy. For 7-10 days after the operation is repeated course of preoperative chemotherapy according to the above scheme and methodology: vincristine 1.4 mg/m2/inkjet - 1 day; adriamycin 70 mg/m2on previously collected autologous blood in a special bottle with logician - the amount of blood - 150 ml, followed by incubation in a thermostat at t= 36,5-37oC for 30 min, and intravenous drip reinfuse - day 2 and depo-provera/m 500 mg - 4th day. When kidney cancer" 1. Patient S. , 14268/K was admitted to the Department of oncourology with complaints hyperthermia - up 38oWith in the evening for 2 months, General weakness, weight loss. After examining the set DS: tumor of the left kidney T3N1M0, gr. II. According to the U.S.: n/a pole of the left kidney bumpy education 8,76,08,0 cm in the upper division of mesogastric paraaortal 2 lymph nodes of 2.8 and 3.0, see The patient received preoperative IGHT. Under ultrasound control: tumor 8,76,2 cm retroperitoneal lymph nodes are not lazerous. Then was fulfilled radical nephrectomy on the left. Intraoperative: vascular leg infiltrated by the tumor. HA 557899-902 moderately-differentiated renal cell carcinoma, clear option with foci of necrosis, with invasion of the capsule. In regional lymph node mts cancer-free. On the 12th day after the operation was repeated course IGHT. Prescribed in III clinical group. The follow-up period was 5 months. Data for recurrence and distant metastases are not. An example of clinical application 2. Patient C. 2392/l entered the urologic Department of RNII with complaints of pain in the lumbar region, which had stopped taking non-narcotic analgesics (baralgin 4-5). For the first time erena surface of the bottom pole extensive education with a clear outline with a diameter of 56 mm The patient was conducted neoadjuvant course IGHT. Clinical effects were stopped pain syndrome, the patient refused analgesics. When the control ultrasound: volume education 5,85,3 cm, on the 10th day the patient was made right radical nephrectomy. HA 566397-98 moderately-differentiated renal cell carcinoma, clear version of invasion of the capsule. Microreport: kidney 755 cm in the lower pole of the tumor site with a diameter of 3 see the Postoperative period without features. On the 10th day - adjuvant course IGHT. Prescribed in III clinical group. The period of follow-up was 8 months. Data for recurrence no. In both cases, was not observed toxic effects of chemotherapy on bone marrow cells. According to the immunological indexes of immune suppression is not marked. Technical and economic efficiency "method of treatment of kidney cancer" is that the application of the method increases the effectiveness of treatment, reduced toxic manifestations, complications hormone disorders, increased relapse-free period, reduced the incidence of distant metastases. The method of treatment available, the course of treatment despite some well tolerated duration of ECENA kidney cancer, including chemotherapy, surgery, characterized in that in the preoperative period spend polychemotherapy according to the scheme: vincristine 1.4 mg/m2/inkjet - day 1; 150 ml of autologous blood type 70 mg/m2of adriamycin, incubated the mixture for 30 min, is re-infused in/drip - 2nd day; 500 mg depo-provera is injected into/m - 4 days; 7-10 days to produce radical nephrectomy, and 7-10 days after the operation, repeat the above polychemotherapy, autohemotherapy and the introduction of depo-provera.
|